Abstract
Objectives
Methods
Results
Conclusions
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to UrologyReferences
Pfizer Inc., New York, NY: Data on file. 2002
- Pharmacokinetics of sildenafil citrate after single oral doses in healthy male subjects.Br J Clin Pharmacol. 2002; 53: 5S-12S
- The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil citrate.Br J Clin Pharmacol. 2002; 53: 21S-30S
- The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers.Br J Clin Pharmacol. 2002; 53: 37S-43S
- Onset and duration of action of sildenafil citrate for the treatment of erectile dysfunction.Br J Clin Pharmacol. 2002; 53: 61S-65S
- Sildenafil, a novel effective oral therapy for male erectile dysfunction.Br J Urol. 1996; 78: 257-261
- Oral sildenafil in the treatment of erectile dysfunction.N Engl J Med. 1998; 338: 1397-1404
- The International Index of Erectile Function (IIEF).Urology. 1997; 49: 822-830
- Regression analysis of multivariate incomplete failure time data by modeling marginal distributions.J Am Stat Assoc. 1989; 84: 1065-1073
- Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients.World J Urol. 2001; 19: 32-39
- Tadalafil.Formulary. 2002; 37: 289-296
- Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose.Eur Urol. 2001; 40: 181-190
- Cialis (IC351) provides prompt response and extended period of responsiveness for the treatment of men with erectile dysfunction.J Urol. 2001; 165: 224
Padma-Nathan H, Kaufman J, and Taylor T: Earliest time to onset of erections with vardenafil determined in an at-home setting. Presented at the 28th Annual Meeting of the American Society of Andrology, March 29–April 2, 2003, Phoenix, Arizona
Article info
Publication history
Footnotes
☆This study was funded by Pfizer Inc.
☆H. Padma-Nathan is a study investigator funded by the sponsor.